Skip to main content

Porcine Acellular Collagen Matrix

Porcine acellular matrices are a family of tissue-derived scaffolds, including dermis, small intestinal submucosa (SIS) and urinary bladder matrix (UBM). Tissue source, crosslinking, decellularization and sterilization affect handling and remodeling; these products are not interchangeable. Avoiding tissue harvest is a practical advantage, but neither an animal origin nor decellularization establishes durable support, freedom from inflammation or suitability for a particular urinary reconstruction.[1][2]

This overview covers material selection and evidence boundaries. See Porcine SIS for that specific material and Decellularized ECM for scaffold research.

Remodeling and product selection​

The intended response is host-cell infiltration and replacement of the scaffold. Clinical remodeling can be incomplete or accompanied by fibrosis, inflammation, infection and loss of mechanical support. A pathology series of patients requiring reintervention after xenograft sacrocolpopexy found different degradation patterns for porcine dermis and SIS, with inflammation and infection in both groups. This selected failure series cannot estimate complication incidence, but it contradicts a guarantee of no foreign-body response.[2]

Use the exact product's current instructions for indication, animal-tissue hypersensitivity precautions, preparation and fixation. Historical Pelvicol or PelviSoft outcomes do not establish the availability or performance of a currently supplied graft. The route and reconstructive purpose also matter: evidence from a sling, vaginal-wall repair, sacrocolpopexy or urethral onlay cannot be transferred automatically to another use.

Urethral and bladder reconstruction​

The EAU 2026 urethral-stricture guideline gives a weak recommendation to avoid cell-free tissue-engineered grafts with extensive spongiofibrosis, a previous failed urethroplasty or a stricture longer than 4 cm. This boundary is not proof that every shorter defect is suitable. The guideline favors buccal or lingual mucosa when a graft is needed and available, and strongly advises against tubularized grafts in a single-stage urethroplasty.[3]

Small salvage reports show feasibility, with important co-interventions. A pediatric report included ten fistula repairs and two redo urethroplasties in 12 boys; one child developed infection requiring debridement. Two female UBM reconstructions also used labial fat-pad transposition and a biologic pubovaginal sling. Neither report establishes equivalence to vascularized tissue or attributes continence to the scaffold alone.[4][5]

Regenerative scaffolds remain a research field. A 2025 TissueSpan report described animal development and initiation of a first human trial, without reporting human outcomes. The 2025 UROGRAFT study investigated a bladder-matrix/collagen/cellulose composite preclinically. These studies do not establish a clinically validated replacement for conventional urethral reconstruction or enterocystoplasty. Animal defect lengths and failure percentages should not become clinical selection thresholds.[6][7]

Stress urinary incontinence​

The most useful long-term comparison concerns Pelvicol porcine dermis, not every porcine scaffold. In the follow-up of a four-centre randomized trial, 162 of 201 women were assessed at a median of ten years. Patient-reported dry-or-improved rates were 58% with Pelvicol, 75.4% with autologous fascia and 73% with TVT; complete dryness was 15.7%, 50.8% and 31.7%, respectively. Complete dryness favored autologous fascia over Pelvicol. These separate endpoints and follow-up losses matter when counseling about durability.[8]

A short uncontrolled series with a high initial cure rate cannot establish long-term equivalence to an autologous fascial sling material or polypropylene sling.

Pelvic organ prolapse​

SettingEvidence and implication
Primary transvaginal anterior/posterior repairThe large multicentre PROSPECT trial found no clinically important symptom or functional-cure advantage from biological xenograft augmentation at six years. About 65% returned six-year questionnaires, and no examination was performed at that time. The result concerns primary vaginal-wall repair; it does not evaluate abdominal sacrocolpopexy or all salvage reconstructions.[9]
Laparoscopic sacrocolpopexyCulligan's single-centre RCT randomized 120 women to PelviSoft crosslinked porcine dermis or polypropylene; 115 completed 12 months. Objective cure was 46/57 (80.7%) versus 50/58 (86.2%). No significant difference was detected, but the trial was designed to detect a large, 23-percentage-point difference. It was not an equivalence or noninferiority trial and cannot establish comparable long-term durability or rare-event safety.[10]

US regulatory scope: the FDA's 2019 stop-sale order for devices intended for transvaginal POP repair included Xenform, a bovine-derived product, as well as synthetic products. It was not confined to synthetic materials. This action should not be generalized to all midurethral slings, abdominal sacrocolpopexy mesh or every biological graft use.[11]

Practical selection questions​

  • What exact tissue, product generation and current labeled use are being considered?
  • Does the evidence match the operation, route, fixation and required duration of support?
  • Is the recipient tissue suitable for incorporation, and what alternatives have better evidence?
  • Are the patient-relevant outcome, follow-up losses and potential need for reoperation clear?

For other materials, see Human ADM, Bovine grafts and Polypropylene mesh.

References​

1. Davis NF, McGuire BB, Callanan A, et al. Xenogenic extracellular matrices as potential biomaterials for interposition grafting in urological surgery. J Urol. 2010;184:2246–2253. doi:10.1016/j.juro.2010.07.038.

2. Deprest J, Klosterhalfen B, Schreurs A, et al. Clinicopathological study of patients requiring reintervention after sacrocolpopexy with xenogenic acellular collagen grafts. J Urol. 2010;183:2249–2255. doi:10.1016/j.juro.2010.02.008.

3. European Association of Urology. Urethral Strictures: Tissue Transfer. 2026. Guideline chapter.

4. Springer A, Subramaniam R. Preliminary experience with the use of acellular collagen matrix in redo surgery for urethrocutaneous fistula. Urology. 2012;80:1156–1160. doi:10.1016/j.urology.2012.06.058.

5. Ansari S, Karram M. Two cases of female urethral reconstruction with acellular porcine urinary bladder matrix. Int Urogynecol J. 2017;28:1257–1260. doi:10.1007/s00192-016-3262-7.

6. Vythilingam G, Larsson HM, Yeoh WS, et al. Off-the-shelf implant to bridge a urethral defect: multicenter 8-year journey from bench to bed. Urology. 2025;196:294–299. doi:10.1016/j.urology.2024.12.016.

7. Pokrywczynska M, Fekner Z, Balcerczyk D, et al. Development of UROGRAFT: a bladder acellular matrix-based composite for advanced cystoplasty. ACS Biomater Sci Eng. 2025. doi:10.1021/acsbiomaterials.5c00700.

8. Khan ZA, Nambiar A, Morley R, et al. Long-term follow-up of a multicentre randomised controlled trial comparing tension-free vaginal tape, xenograft and autologous fascial slings for the treatment of stress urinary incontinence in women. BJU Int. 2015;115:968–977. doi:10.1111/bju.12851.

9. Reid FM, Aucott L, Glazener CMA, et al. PROSPECT: 4- and 6-year follow-up of a randomised trial of surgery for vaginal prolapse. Int Urogynecol J. 2023;34:67–78. doi:10.1007/s00192-022-05308-0.

10. Culligan PJ, Salamon C, Priestley JL, Shariati A. Porcine dermis compared with polypropylene mesh for laparoscopic sacrocolpopexy: a randomized controlled trial. Obstet Gynecol. 2013;121:143–151. doi:10.1097/AOG.0b013e31827558dc.

11. US Food and Drug Administration. Urogynecologic Surgical Mesh Implants. Regulatory scope.